三星生物制药拟18亿美元收购瑞士多肽集团Samsung Biologics to Acquire Swiss PolyPeptide Group for $1.8 Billion
韩国三星生物制药公司于2026年7月20日宣布，已向瑞士多肽集团（PolyPeptide Group）发起一项总额为14.6亿瑞士法郎（约合18亿美元）的全现金公开要约收购。根据交易条款，多肽集团的股东将获得每股44.31瑞士法郎的现金，该笔交易预计将于2026年年底前完成。三星生物制药表示，这是韩国历史上规模最大的生物制药并购交易，旨在通过进军多肽疗法来实现业务多元化。当前，由于肥胖症治疗需求激增，多肽疗法已成为生物制药行业增长最快的领域之一。多肽集团董事会主席彼得·维尔登（Peter Wilden）表示，董事会在对战略选择进行全面评估后，确信该报价对股东而言具有吸引力，能够提供确定的即时价值。受此消息影响，多肽集团股价在周一早盘交易中上涨了近5.3%。此项收购也是韩国企业通过海外并购进行国际化扩张的最新典型案例。
South Korea's Samsung Biologics announced on Monday, July 20, 2026, that it has launched an all-cash public tender offer of 1.46 billion Swiss francs ($1.8 billion) to acquire Switzerland's PolyPeptide Group. Under the terms of the offer, stockholders of the Swiss peptide manufacturer will receive 44.31 Swiss francs per share, with the transaction expected to close by the end of 2026. Samsung Biologics stated that this acquisition represents the largest biopharmaceutical M&A deal in South Korea's history, aimed at diversifying its portfolio into peptide therapeutics, which is currently one of the fastest-growing segments in the industry due to surging demand for obesity treatments. PolyPeptide's board of directors has backed the proposal, with chairman Peter Wilden stating that the board is convinced the offer is compelling and delivers immediate, certain value to shareholders. Following the announcement, PolyPeptide shares rose by nearly 5.3% in morning trading, marking the latest example of South Korean companies expanding their global footprint through international acquisitions.
01收购要约与交易条款Acquisition Offer and Transaction Terms
根据三星生物制药公布的官方条款，此次针对瑞士多肽集团发起的公开要约收购将完全以现金形式进行。三星生物制药计划支付总计14.6亿瑞士法郎（约合18亿美元）的资金，以获取这家专门从事多肽活性药物成分制造的瑞士企业的控制权。在这项公开要约收购中，多肽集团的持股人将可以凭借其持有的每股股份，换取44.31瑞士法郎的现金对价。
According to the official terms announced by Samsung Biologics, the public tender offer for Switzerland's PolyPeptide Group will be executed entirely in cash. The South Korean biopharmaceutical company has launched a bid totaling 1.46 billion Swiss francs, which is equivalent to approximately $1.8 billion, to acquire the Swiss firm that specializes in peptide-based active pharmaceutical ingredients.
该笔全现金交易目前正处于推进阶段，双方预计整个收购流程和相关交割工作将在2026年年底前完成。作为交易标的，瑞士多肽集团在生物制药领域具有独特的定位，其核心业务专注于多肽类活性药物成分的研发与生产。此次收购要约的条款已经过双方确认，后续将按照既定的时间表和法律程序逐步落实。
Under the specific provisions of this public tender offer, PolyPeptide stockholders are set to receive a cash payment of 44.31 Swiss francs per share. The entire transaction is currently on track and is expected to officially close by the end of this year, establishing a clear timeline for the completion of this major international acquisition.
02进军多肽疗法与肥胖症治疗市场Strategic Expansion into Peptide Therapeutics
三星生物制药将此次收购定位为其历史上规模最大的生物制药并购交易，旨在通过进军多肽疗法来实现其业务组合的多元化。多肽疗法由短链氨基酸制成，目前已成为生物制药行业中增长最快的细分领域之一。这一增长主要受到全球对肥胖症治疗需求激增的推动。
Samsung Biologics has positioned this acquisition as the largest biopharmaceutical M&A transaction in South Korea's history, designed to diversify its business portfolio by expanding into peptide therapeutics. Peptide therapeutics represent one of the fastest-growing segments within the broader biopharmaceutical industry, a rapid expansion driven primarily by the surging global demand for obesity treatments.
在多肽疗法中，最受关注的包括部分GLP-1肥胖与糖尿病药物。这类药物通过模拟人体内的天然激素来发挥作用，从而达到抑制食欲和调节血糖的效果。通过将瑞士多肽集团纳入旗下，三星生物制药能够直接获取多肽活性药物成分的制造能力，从而在这个快速扩张的医疗市场中占据一席之地。
These therapeutic medicines are made from short chains of amino acids and include certain GLP-1 obesity and diabetes drugs. These specific treatments function by mimicking a natural hormone in the human body to reduce appetite and regulate blood sugar levels. Through this acquisition, Samsung Biologics secures direct access to specialized peptide-based active pharmaceutical ingredients to capture share in this high-growth market.
03董事会态度与市场反应Board Recommendation and Market Reaction
瑞士多肽集团董事会对三星生物制药提出的收购要约表示了明确支持。董事会主席彼得·维尔登（Peter Wilden）表示，在对公司的战略选择进行全面评估后，董事会确信三星生物制药的这一报价对股东而言极具吸引力。维尔登强调，该要约不仅提供了极具吸引力的现金价格，还为股东带来了确定的即时价值。
The board of directors of Switzerland's PolyPeptide Group has expressed strong support for the acquisition proposal. Peter Wilden, the chairman of PolyPeptide, stated that after conducting a comprehensive review of the company's strategic options, the board is fully convinced that the offer from Samsung Biologics is compelling for its shareholders. Wilden noted that the bid delivers an attractive cash price along with immediate and certain value.
受此收购消息推动，多肽集团在资本市场上的表现强劲。在周一早盘交易中，多肽集团的股价上涨了近5.3%，反映出投资者对该笔交易的积极预期。这一市场反应与董事会的支持态度相呼应，显示出市场对两家公司合并前景的乐观态度。
Following the announcement of the acquisition, PolyPeptide's shares experienced a positive reaction in the financial markets. The company's stock price rose by nearly 5.3% during morning trading, reflecting favorable investor sentiment toward the transaction. This upward movement in share price aligned with the board's recommendation, indicating market confidence in the proposed deal.
04韩国企业海外扩张新动向South Korean Corporate Expansion Abroad
三星生物制药对瑞士多肽集团发起的这项收购，成为韩国企业通过海外并购进行国际化扩张的最新典型案例。近年来，韩国企业在寻求全球化增长的过程中，越来越多地将目光投向海外市场，通过收购具有技术优势或特定市场份额的境外企业来加速自身的国际化布局。
The acquisition of PolyPeptide Group by Samsung Biologics serves as the latest example of South Korean companies expanding their global footprint through international acquisitions. In their pursuit of global growth, South Korean firms have increasingly turned to outbound mergers and acquisitions to accelerate their international expansion by absorbing foreign companies with specialized technical capabilities and established market positions.
此次针对多肽集团的收购不仅刷新了韩国生物制药领域的并购规模纪录，也展示了韩国企业在医疗健康和生物技术等高增长行业中，通过跨境交易获取核心资产与制造能力的战略选择。这种海外扩张模式正在帮助韩国企业在国际竞争中建立更广泛的全球足迹。
This transaction not only sets a new milestone as the largest biopharmaceutical merger and acquisition deal in South Korea's history, but also highlights a broader corporate trend. South Korean enterprises are actively deploying capital abroad to secure core manufacturing assets and specialized capabilities in high-growth sectors, thereby strengthening their competitive positioning in the global marketplace.
